drugset / Trial / NCT01499368

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients

NCT01499368

Phase 3 Completed 495 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the healing rate and safety of Lafutidine in erosive esophagitis

Timeline

Start
2011-11
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Famotidine Other / unclassified 40 mg
Subject Lafutidine Small molecule 20 mg
Subject Omeprazole Other / unclassified 20 mg

Indications